Cargando…
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan
Natural killer cell responses play a crucial role in virus clearance by the innate immune system. Although the killer immunoglobulin-like receptor (KIR) in combination with its cognate human leukocyte antigen (HLA) ligand, especially KIR2DL3-HLA-C1, is associated with both treatment-induced and spon...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861489/ https://www.ncbi.nlm.nih.gov/pubmed/24349500 http://dx.doi.org/10.1371/journal.pone.0083381 |
_version_ | 1782295647903285248 |
---|---|
author | Nozawa, Yuichi Umemura, Takeji Joshita, Satoru Katsuyama, Yoshihiko Shibata, Soichiro Kimura, Takefumi Morita, Susumu Komatsu, Michiharu Matsumoto, Akihiro Tanaka, Eiji Ota, Masao |
author_facet | Nozawa, Yuichi Umemura, Takeji Joshita, Satoru Katsuyama, Yoshihiko Shibata, Soichiro Kimura, Takefumi Morita, Susumu Komatsu, Michiharu Matsumoto, Akihiro Tanaka, Eiji Ota, Masao |
author_sort | Nozawa, Yuichi |
collection | PubMed |
description | Natural killer cell responses play a crucial role in virus clearance by the innate immune system. Although the killer immunoglobulin-like receptor (KIR) in combination with its cognate human leukocyte antigen (HLA) ligand, especially KIR2DL3-HLA-C1, is associated with both treatment-induced and spontaneous clearance of hepatitis C virus (HCV) infection in Caucasians, these innate immunity genes have not been fully clarified in Japanese patients. We therefore investigated 16 KIR genotypes along with HLA-B and -C ligands and a genetic variant of interleukin (IL) 28B (rs8099917) in 115 chronic hepatitis C genotype 1 patients who underwent pegylated-interferon-α2b (PEG-IFN) and ribavirin therapy. HLA-Bw4 was significantly associated with a sustained virological response (SVR) to treatment (P = 0.017; odds ratio [OR] = 2.50, ), as was the centromeric A/A haplotype of KIR (P = 0.015; OR 3.37). In contrast, SVR rates were significantly decreased in patients with KIR2DL2 or KIR2DS2 (P = 0.015; OR = 0.30, and P = 0.025; OR = 0.32, respectively). Multivariate logistic regression analysis subsequently identified the IL28B TT genotype (P = 0.00009; OR = 6.87, 95% confidence interval [CI] = 2.62 - 18.01), KIR2DL2/HLA-C1 (P = 0.014; OR = 0.24, 95% CI = 0.08 - 0.75), KIR3DL1/HLA-Bw4 (P = 0.008, OR = 3.32, 95% CI = 1.37 - 8.05), and white blood cell count at baseline (P = 0.009; OR = 3.32, 95% CI = 1.35 - 8.16) as independent predictive factors of an SVR. We observed a significant association between the combination of IL28B TT genotype and KIR3DL1-HLA-Bw4 in responders (P = 0.0019), whereas IL28B TT along with KIR2DL2-HLA-C1 was related to a non-response (P = 0.0067). In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV. |
format | Online Article Text |
id | pubmed-3861489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38614892013-12-17 KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan Nozawa, Yuichi Umemura, Takeji Joshita, Satoru Katsuyama, Yoshihiko Shibata, Soichiro Kimura, Takefumi Morita, Susumu Komatsu, Michiharu Matsumoto, Akihiro Tanaka, Eiji Ota, Masao PLoS One Research Article Natural killer cell responses play a crucial role in virus clearance by the innate immune system. Although the killer immunoglobulin-like receptor (KIR) in combination with its cognate human leukocyte antigen (HLA) ligand, especially KIR2DL3-HLA-C1, is associated with both treatment-induced and spontaneous clearance of hepatitis C virus (HCV) infection in Caucasians, these innate immunity genes have not been fully clarified in Japanese patients. We therefore investigated 16 KIR genotypes along with HLA-B and -C ligands and a genetic variant of interleukin (IL) 28B (rs8099917) in 115 chronic hepatitis C genotype 1 patients who underwent pegylated-interferon-α2b (PEG-IFN) and ribavirin therapy. HLA-Bw4 was significantly associated with a sustained virological response (SVR) to treatment (P = 0.017; odds ratio [OR] = 2.50, ), as was the centromeric A/A haplotype of KIR (P = 0.015; OR 3.37). In contrast, SVR rates were significantly decreased in patients with KIR2DL2 or KIR2DS2 (P = 0.015; OR = 0.30, and P = 0.025; OR = 0.32, respectively). Multivariate logistic regression analysis subsequently identified the IL28B TT genotype (P = 0.00009; OR = 6.87, 95% confidence interval [CI] = 2.62 - 18.01), KIR2DL2/HLA-C1 (P = 0.014; OR = 0.24, 95% CI = 0.08 - 0.75), KIR3DL1/HLA-Bw4 (P = 0.008, OR = 3.32, 95% CI = 1.37 - 8.05), and white blood cell count at baseline (P = 0.009; OR = 3.32, 95% CI = 1.35 - 8.16) as independent predictive factors of an SVR. We observed a significant association between the combination of IL28B TT genotype and KIR3DL1-HLA-Bw4 in responders (P = 0.0019), whereas IL28B TT along with KIR2DL2-HLA-C1 was related to a non-response (P = 0.0067). In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV. Public Library of Science 2013-12-12 /pmc/articles/PMC3861489/ /pubmed/24349500 http://dx.doi.org/10.1371/journal.pone.0083381 Text en © 2013 Nozawa et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Nozawa, Yuichi Umemura, Takeji Joshita, Satoru Katsuyama, Yoshihiko Shibata, Soichiro Kimura, Takefumi Morita, Susumu Komatsu, Michiharu Matsumoto, Akihiro Tanaka, Eiji Ota, Masao KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title |
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title_full |
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title_fullStr |
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title_full_unstemmed |
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title_short |
KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan |
title_sort | kir, hla, and il28b variant predict response to antiviral therapy in genotype 1 chronic hepatitis c patients in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861489/ https://www.ncbi.nlm.nih.gov/pubmed/24349500 http://dx.doi.org/10.1371/journal.pone.0083381 |
work_keys_str_mv | AT nozawayuichi kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT umemuratakeji kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT joshitasatoru kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT katsuyamayoshihiko kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT shibatasoichiro kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT kimuratakefumi kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT moritasusumu kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT komatsumichiharu kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT matsumotoakihiro kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT tanakaeiji kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan AT otamasao kirhlaandil28bvariantpredictresponsetoantiviraltherapyingenotype1chronichepatitiscpatientsinjapan |